What does Bonus BioGroup Ltd. do?

Bonus BioGroup Ltd. (BONS.TA) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is BONS.TA's market cap?

Bonus BioGroup Ltd. (BONS.TA) has a market capitalization of approximately $23.48 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does BONS.TA pay a dividend?

No — Bonus BioGroup Ltd. (BONS.TA) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is BONS.TA profitable?

Bonus BioGroup Ltd. (BONS.TA) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

BONS.TA

Bonus BioGroup Ltd.

TLV·Biotechnology · Healthcare

ILA 20.10ILA 0.30+1.52%

Market capILA 23.48B·Aug 26 12:44 PM UTC

Price Chart

ILA 20.10+ILA 0.30 (+1.52%)today

−86.76%CAGR −33.26%

Select date range

FromTo

Aug 12, 2002Aug 26, 2021 → Aug 26, 2026· 5.0 yrsAug 26, 2026

Key Metrics

BONS.TA does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateNov 13

Last Report DateDec 31

Reported vs Estimate−ILA 0.01

Earnings Surprise—

FinancialsFinancials Tab

Revenue₪0.00

Net Income−₪24.49M

Net Margin—

Operating Cash Flow−₪14.93M

Capital Expenditures₪12.00K

Free Cash Flow−₪14.95M

Return on Equity—

Return on Invested Capital−177.8%

Net Debt₪8.67M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for BONS.TA and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how BONS.TA's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BONS.TA and 80,000+ other tickers.

About Bonus BioGroup Ltd.

Bonus BioGroup Ltd. is a clinical-stage biotechnology firm dedicated to creating therapeutic solutions through tissue engineering and cell-based therapies. Their flagship products include BonoFill, which is developed for regenerating bone tissue in maxillofacial and orthopedic applications, and MesenCure, aimed at treating COVID-19 patients suffering from pneumonia and acute respiratory distress syndrome (ARDS), as well as other life-threatening acute inflammatory illnesses. The company's innovation pipeline encompasses bone augmentation treatments for individuals with osteoporosis…

CEO: Shai Meretzki
Sector: Healthcare
Industry: Biotechnology
Exchange: TLV
Employees: 42
Website: bonus-bio.com

Peers

Oramed Pharmaceuticals Inc.

Cap

ILA 65.6B

Latest News

News Tab

No recent news available.

Frequently Asked Questions About BONS.TA

What does Bonus BioGroup Ltd. do?: Bonus BioGroup Ltd. (BONS.TA) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is BONS.TA's market cap?: Bonus BioGroup Ltd. (BONS.TA) has a market capitalization of approximately $23.48 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does BONS.TA pay a dividend?: No — Bonus BioGroup Ltd. (BONS.TA) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is BONS.TA profitable?: Bonus BioGroup Ltd. (BONS.TA) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.